INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 222 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1 | -100.0% | 54,200 | +1.1% | 0.00% | – |
| Q3 2022 | $6,000 | +50.0% | 53,600 | +17.8% | 0.00% | – |
| Q2 2022 | $4,000 | -42.9% | 45,500 | +18.2% | 0.00% | – |
| Q1 2022 | $7,000 | -96.6% | 38,500 | -71.9% | 0.00% | -100.0% |
| Q4 2021 | $203,000 | -47.7% | 137,100 | -6.1% | 0.01% | -53.8% |
| Q3 2021 | $388,000 | +48.1% | 146,083 | -39.2% | 0.01% | +62.5% |
| Q2 2021 | $262,000 | -48.4% | 240,300 | +40.0% | 0.01% | -71.4% |
| Q1 2021 | $508,000 | +74.6% | 171,655 | +12.0% | 0.03% | +250.0% |
| Q4 2020 | $291,000 | -46.3% | 153,200 | -45.4% | 0.01% | -70.4% |
| Q3 2020 | $542,000 | -55.9% | 280,800 | +34.0% | 0.03% | -59.7% |
| Q2 2020 | $1,230,000 | +1094.2% | 209,500 | +158.6% | 0.07% | +857.1% |
| Q1 2020 | $103,000 | +635.7% | 81,000 | +686.4% | 0.01% | +600.0% |
| Q1 2018 | $14,000 | -33.3% | 10,300 | -1.9% | 0.00% | 0.0% |
| Q4 2017 | $21,000 | +425.0% | 10,500 | -30.5% | 0.00% | – |
| Q1 2017 | $4,000 | – | 15,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |